Aldeyra Therapeutics is a biotechnology company engaged in developing and commercializing medicines for patients with immune-mediated diseases. The company's primary product candidate, reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. The company has additional product candidates in development for proliferative vitreoretinopathy and other retinal diseases, autoimmune disease, and cancer. The company has discovered and are developing two additional reactive aldehyde species inhibitors, ADX-103 and ADX-629, for the treatment of retinal disease and autoimmune disease, respectively.

Alector is a clinical stage biopharmaceutical company. The company is engaged in developing immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The company's preclinical and clinical programs include: AL001, which is the company's progranulin (PGRN) product candidate in clinical development, is designed to treat frontotemporal dementia, a severe, rapidly progressing neurodegenerative disorder: AL101, which is the company's second PGRN product candidate that is being developed for the indications, such as Alzheimer's disease and Parkinson's disease; and AL002 and AL003, which are candidate for Alzheimer's disease.

AnaptysBio is a clinical stage biotechnology company developing antibody product candidates. Etokimab, the company's anti-IL-33 antibody drug candidate, inhibits the activity of the interleukin-33 cytokine that is applicable to the treatment of atopic inflammatory disorders, such as moderate-to-severe atopic dermatitis, eosinophilic asthma, chronic rhinosinusitis with nasal polyps, and potentially other allergic conditions. ANB019 inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases including generalized pustular psoriasis and palmoplantar pustulosis. The company's wholly-owned pipeline includes anti-inflammatory checkpoint receptor modulator antibodies.

bluebird bio is a biotechnology company engaged in researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. The company has built a product platform with a range of therapeutic potential in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. The company is developing LentiGlobin gene therapy for sickle cell disease; Lenti-D gene therapy for cerebral adrenoleukodystrophy; and in collaboration with Bristol-Myers Squibb, the company is developing bb2121 (idecabtagene vicleucel) and bb21217 product candidates as treatments for multiple myeloma.

Cavco Industries designs and produces factory-built homes distributed through a network of independent and the company-owned retailers, planned community operators and residential developers, marketed under a variety of brand names including Cavco, Fleetwood, Palm Harbor, Fairmont, Friendship, Chariot Eagle and Lexington. The company is also a producer of park model RVs, vacation cabins and systems-built commercial structures, as well as modular homes built under the Nationwide Homes brand. Each home contains a living room, dining area, kitchen, one to five bedrooms and one or more bathrooms, is equipped with central heat and hot water systems, kitchen appliances, floor coverings and window treatments.

Celldex Therapeutics is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company has four drug candidates in clinical development, including CDX-1140, an agonist human monoclonal antibody targeted to CD40, a key activator of immune response; CDX-3379, a human monoclonal antibody designed to block the activity of ErbB3; varlilumab, an immune modulating antibody targeting CD27 designed to improve a patient's immune response; and CDX-301, a dendritic cell growth factor.

Clearfield designs, manufactures and distributes fiber protection, fiber management and fiber delivery solutions. The company's products include: FieldSmart?, which provides a design from the inside plant of the telco's central office or cable television's head-end, all the way through the outside plant to the access network to within the home or business; WaveSmart? optical components, which are integrated for signal coupling, splitting, termination, multiplexing, demultiplexing and attenuation for an integration within the company's fiber management platform; and ODC outdoor active cabinet product line, which features a line of cabinets equipped with specific active electronics configurations.

CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company's primary focus is on the development of its primary product candidate, Neutrolin?, for potential commercialization in the United States and other main markets. The company has in-licensed the worldwide rights to develop and commercialize Neutrolin. Neutrolin is an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as dialysis, critical/intensive care, and oncology.

Crocs is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear and accessories for men, women, and children. The company provides a variety of footwear products including sandals, flips and slides, which the company collectively refer to as sandals, shoes, and boots. The majority of shoes within the company's collection contains Croslite? material. The company's wholesale channel includes domestic and international multi-brand retailers, e-tailers, and distributors; the company's retail channel consists of company-operated stores; and the company's e-commerce channel includes company-operated e-commerce sites and third-party marketplaces.

Dynavax Technologies is a biopharmaceutical company focused on utilizing the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's commercial product, HEPLISAV-B? (Hepatitis B Vaccine (Recombinant), Adjuvanted), is approved for prevention of infection caused by various known subtypes of hepatitis B virus in adults age 18 years and older. The company's development efforts are focused on stimulating the innate immune response to treat cancer in combination with other immunomodulatory agents. The company's pipeline of product candidates includes: SD-101, which is its cancer immunotherapy candidate; and DV281, which is an investigational TLR9 agonist.

FAT Brands is a multi-brand restaurant franchising company that develops, markets, and acquires fast casual restaurant concepts. The company's restaurant brands include: Fatburger, which serves a variety of customizable Fatburgers, Turkeyburgers, Chicken Sandwiches, Impossible? Burgers, and Veggieburgers, among other; Buffalo's Cafe, which provides chicken wings and homemade wing sauces, burgers, and wraps, among other; Ponderosa and Bonanza Steakhouse, which provide guests a buffet and an array of steak, chicken and seafood entrees; Hurricane Grill & Wings, which provides chicken wings, sauces, burgers, and bowls, among other; and Yalla Mediterranean, which focuses on Mediterranean cuisine.

Fox Factory Holding is a holding company. Through its subsidiaries, the company is a designer, manufacturer and marketer of products and systems used on bicycles, side-by-side vehicles, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, all-terrain vehicles, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. In its powered vehicle product categories, the company provides products under the FOX, BDS Suspension, Zone Offroad, JKS Manufacturing, RT Pro UTV, 4x4 Posi-Lok, and Tuscany brands. The company's bike product offerings are used on a range of mountain bikes and road bikes under the FOX, Race Face, Easton Cycling and Marzocchi brands.

G1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company's product pipeline includes three clinical candidates: trilaciclib, a short-acting intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that preserves hematopoietic stem and progenitor cells and immune system function; lerociclib, an oral CDK4/6 inhibitor that inhibits tumor proliferation and growth; and G1T48, an oral selective estrogen receptor degrader that inhibits estrogen receptor driven tumor proliferation.

inTEST is an independent designer, manufacturer and marketer of thermal management products and automated test equipment (ATE) interface solutions which are used by semiconductor manufacturers to perform development, qualifying and final testing of integrated circuits (ICs) and wafers, and for other electronic testing across a range of industries including the automotive, defense/aerospace, energy, industrial and telecommunications markets. The company also provides induction heating products for joining and forming metals in a variety of industrial markets, including automotive, aerospace, machinery, wire and fasteners, medical, semiconductor, food and beverage, and packaging.

Joint Corp is a franchisor and operator of chiropractic clinics that uses a private pay, non-insurance, cash-based model. The company's principal business is to develop, own, operate, support and manage chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The company's clinics provides a variety of customizable membership and wellness treatment plans. Each patient's records are digitally updated for retrieval in its proprietary data storage system by the company's chiropractors in compliance with all applicable medical records security and privacy regulations.

Kingsway Financial Services is a holding company. Through its subsidiaries, Co. operates as a merchant bank engaged in the property and casualty insurance business. Co. operates three segments: Insurance Underwriting, which markets automobile insurance products that provide coverage in three main areas: liability, accident benefits and physical damage; Insurance Services, which includes IWS Acquisition Corporation, a licensed motor vehicle service agreement company, and Trinity Warranty Solutions LLC, a provider of warranty products and maintenance support; and Leased Real Estate, which includes Co.'s subsidiary, CMC Industries, Inc., that owns a parcel of real property located in Texas.

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's pipeline consists of two clinical-stage product candidates, maralixibat and volixibat, with mechanisms of action that have potential utility across a wide range of orphan liver diseases.

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. The company's drug product OMIDRIA? is marketed in the U.S. for use during cataract surgery or intraocular lens replacement. In its pipeline the company has clinical-stage development programs focused on: complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; and addictive and compulsive disorders.

OrthoPediatrics is a medical device company that designs, develops and markets anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies designed to meet their needs. The company sells its products, including PediLoc?, PediPlates?, Cannulated Screws, PediFlex? nail, PediNail?, PediLoc? Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Orthex, and QuickPack?, to hospitals and medical facilities throughout the United States and other international markets.

Penumbra is a healthcare company. The company designs, develops, manufactures and markets medical devices. The company's Neuro products include Penumbra System brand of products that provides a form of mechanical thrombectomy used by specialist physicians to revascularize blood vessels that are blocked by clots in the intracranial vasculature. The company's Vascular products include the Ruby Coil System that consists of detachable coils and is used in clinical applications auch as active extravasations, or the escape of blood into surrounding tissue, selective embolization in patients with visceral aneurysms, embolization in patients with gastrointestinal bleeding, and high flow arterial venous malformations.

Progyny operates as a fertility benefits management company in the United States. The company offers patients a benefits solution with education and guidance from a Patient Care Advocate and access to a network of fertility specialists. The company also aims to reduce healthcare costs for employers through their operations.

Reinsurance Group of America is an insurance holding company. Through its subsidiaries, the company is a provider of life and health reinsurance and financial solutions. The company is engaged in providing reinsurance, which includes individual and group life and health, disability, and critical illness reinsurance. The company also provides financial solutions, which includes longevity reinsurance, asset-intensive products, primarily annuities, financial reinsurance, capital solutions and stable value products. The company has five geographic-based and business-based operational segments: United States and Latin America, Canada, Europe, Middle East and Africa, Asia Pacific, and Corporate and Other.

Rhythm Pharmaceuticals is a biopharmaceutical company. The company's primary product candidate is setmelanotide, which is a melanocortin-4 (MC4) receptor agonist peptide for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The company is evaluating setmelanotide for the treatment of six single gene related MC4 pathway deficiencies: pro-opiomelanocortin (POMC), leptin receptor, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.

Sangamo BioSciences is a clinical stage biotechnology company focused on translating science into genomic medicines using its platform technologies in gene therapy and in vivo genome regulation. The company is focused on these therapeutic areas: inherited metabolic diseases, central nervous system diseases and inflammatory and autoimmune diseases. The company is evaluating its wholly-owned investigational ST-920 gene therapy for Fabry disease, an inherited metabolic disease. Under its agreement with Sanofi Genzyme, the company is developing ST-400 and BIVV-003, ex vivo gene-edited cell therapies, for hemoglobinopathies including transfusion dependent beta thalassemia and sickle cell disease.

Sensus Healthcare is a medical device company focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The company uses a proprietary low-energy X-ray technology known as superficial radiation therapy (SRT). The company has incorporated SRT into its portfolio of treatment devices: the SRT-100?, which is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; SRT-100+?, which provides the all same features as the SRT-100, with the addition of remote diagnostics; and SRT-100 Vision?, which provides customers with additional options compared to the SRT-100 base model.

TransMedics is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company developed the Organ Care System ("OCS") to replace a decades-old standard of care. The OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ optimization and assessment. The company's OCS technology replicates many aspects of the organ's natural living and functioning environment outside of the human body.

Twist Bioscience is a synthetic biology company. The company is developing a disruptive DNA synthesis platform to industrialize the engineering of biology. The main of its platform is a proprietary technology that manufactures synthetic DNA by writing DNA on a silicon chip. The company has combined this technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create a technology platform. The company's offerings consists of two primary products that address different needs of its customers across a variety of applications: synthetic genes, oligonucleotide (oligo) pools, next generation sequencing tools and DNA libraries.

Viad is an experiential services company with operations in the U.S., Canada, the U.K., continental Europe, and the United Arab Emirates. The company operates through two business groups: GES U.S. and GES International, which is a live events company that produces exhibitions, conferences, corporate events, and consumer events including audio-visual services from technology to content and design, along with registration, data analytics, engagement, and online tools powered that help clients manage their events; and Pursuit, which is a collection of travel experiences that include recreational attractions, hotels and lodges, food and beverage, retail, sightseeing, and ground transportation services.